Inventor
HEDVAT MICHAEL
US17 patents
⚠️ This page may combine multiple inventors who share the name “HEDVAT MICHAEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
XENCOR INC
16 patentsUS10793632B2Oct 6, 2020
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
XENCOR INC22 citations94
US10787518B2Sep 29, 2020
Bispecific checkpoint inhibitor antibodies
XENCOR INC15 citations94
US11591401B2Feb 28, 2023
Anti-CD28 compositions
XENCOR INC19 citations93
US11377477B2Jul 5, 2022
PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
XENCOR INC7 citations85
US11919958B2Mar 5, 2024
Anti-CD28 compositions
XENCOR INC9 citations84
US10981992B2Apr 20, 2021
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
XENCOR INC6 citations84
US11236170B2Feb 1, 2022
Bispecific checkpoint inhibitor antibodies
XENCOR INC1 citations73
US11919956B2Mar 5, 2024
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
XENCOR INC4 citations72
US11851466B2Dec 26, 2023
Targeted IL-12 heterodimeric Fc-fusion proteins
XENCOR INC3 citations72
US12152076B2Nov 26, 2024
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
XENCOR INC0 citations62
US12006345B2Jun 11, 2024
Untargeted and targeted IL-10 Fc-fusion proteins
XENCOR INC0 citations62
US11312770B2Apr 26, 2022
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
XENCOR INC1 citations62
US11492407B2Nov 8, 2022
Bispecific checkpoint inhibitor antibodies
XENCOR INC0 citations61
US12404329B2Sep 2, 2025
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
XENCOR INC0 citations60
US12378326B2Aug 5, 2025
Anti-CD28 x anti-PSMA antibodies
XENCOR INC0 citations57
US12365743B2Jul 22, 2025
Anti-CD28 x anti-PSMA antibodies
XENCOR INC0 citations57